The Chiron Approach to (3 R,3 aS,6 aR)-Hexahydrofuro[2,3- b]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir

J Org Chem. 2021 Jan 1;86(1):1216-1222. doi: 10.1021/acs.joc.0c02396. Epub 2020 Dec 3.

Abstract

We describe an enantioselective synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol which is a key subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2-O-isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-aldehyde derivative. This optically active ligand alcohol was converted to darunavir efficiently.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Darunavir
  • Furans
  • HIV Protease Inhibitors* / pharmacology
  • HIV-1*
  • Humans
  • Pharmaceutical Preparations*
  • Stereoisomerism
  • Viral Vaccines

Substances

  • Furans
  • HIV Protease Inhibitors
  • Pharmaceutical Preparations
  • Viral Vaccines
  • chiron
  • Darunavir